as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 28 Sep 2026
₹208.8
Change
-8.78 (-4.04%)
Open
₹218.0
Prev. Close
₹217.58
Day High
₹219.86
Day Low
₹207.64
Volume Analysis
Traded
611,079
Delivered
259,508
Delivery %
42.47%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (2)
- •Low return on equity (2.21%)
- •Below-average fundamentals quality score (43/100)
Opportunities (0)
No signal for this stock
Threats (1)
- •FII holding has been falling
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹228.78 | ₹224.32 | ₹216.56 | ₹212.1 | ₹204.34 | ₹199.88 | ₹192.12 |
| Fibonacci | ₹224.32 | ₹219.65 | ₹216.77 | ₹212.1 | ₹207.43 | ₹204.55 | ₹199.88 |
| Camarilla | ₹212.16 | ₹211.04 | ₹209.92 | ₹212.1 | ₹207.68 | ₹206.56 | ₹205.44 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
-7.99%
1 Week
-8.02%
1 Month
+2.24%
3 Months
-4.64%
6 Months
+29.72%
1 Year
-16.63%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
DuPont ROE Breakdown
-2.78%
Net margin -1.96% × asset turnover 0.72x × equity multiplier 1.97x
Company Overview
Sector
Healthcare
Market Cap
₹2,687 Cr
P/E (TTM)
63.4
ROE
2.21%
Book Value
₹97.2
Face Value
₹2.0
Source: Screener.in (Consolidated figures) — data as of 29 Sep 2026. Not investment advice.
TopFund Analysis
Hikal Limited scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 43/100. The strongest factor is Financial Strength (84/100), while Growth (0/100) is the weakest area to weigh before deciding. Notably: Low return on equity (2.21%); below-average fundamentals quality score (43/100). FII holding has been falling.
TopFund Score — Fundamentals Quality
43/100 — WeakData confidence: 75/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 28 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- −Company has low interest coverage ratio.
- −The company has delivered a poor sales growth of -0.09% over past five years.
- −Company has a low return on equity of 5.16% over last 3 years.
- −Dividend payout has been low at 8.37% of profits over last 3 years
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Crisil ESG assigned Hikal an ESG rating of 65 for FY 2025-26.
Shareholders approve Sameer Hiremath as CMD from Oct 1, 2026; Hikal starts personal care production at Panoli, Gujarat.
Hikal’s 38th AGM on September 23, 2026 approved six resolutions, including ₹0.60 dividend and Sameer Hiremath’s appointment.
Hikal AGM on Sept. 23, 2026 approved all 6 resolutions, including ₹0.60 dividend and CMD appointment.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 388 | 435 | 448 | 514 | 407 | 453 | 448 | 552 | 380 | 319 | 494 | 519 | 403 |
| Expenses + | 338 | 377 | 383 | 420 | 349 | 378 | 376 | 429 | 355 | 311 | 412 | 414 | 366 |
| Operating Profit | 50 | 58 | 65 | 94 | 58 | 75 | 72 | 123 | 25 | 7 | 83 | 105 | 37 |
| OPM % | 12.96% | 13.23% | 14.46% | 18.36% | 14.26% | 16.54% | 16.1% | 22.34% | 6.6% | 2.26% | 16.73% | 20.29% | 9.19% |
| Other Income + | 1 | 1 | 0 | 1 | 1 | 0 | 4 | 1 | 1 | 2 | -35 | -41 | 11 |
| Interest | 14 | 13 | 14 | 15 | 20 | 19 | 19 | 18 | 17 | 15 | 16 | 15 | 15 |
| Depreciation | 28 | 29 | 29 | 32 | 32 | 32 | 33 | 38 | 39 | 41 | 41 | 42 | 43 |
| Profit before tax | 10 | 17 | 22 | 47 | 7 | 25 | 24 | 68 | -30 | -47 | -9 | 8 | -10 |
| Tax % | 28.87% | 25.44% | 25.46% | 28.33% | 26.09% | 26.21% | 27.73% | 26.5% | -26.32% | -25.74% | -35.87% | -73.49% | -25.25% |
| Net Profit + | 7 | 13 | 16 | 34 | 5 | 18 | 17 | 50 | -22 | -35 | -6 | 14 | -7 |
| EPS in Rs | 1 | 1 | 1 | 3 | 0 | 1 | 1 | 4 | -2 | -3 | 0 | 1 | -1 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 872 | 926 | 1,014 | 1,296 | 1,590 | 1,507 | 1,720 | 1,943 | 2,023 | 1,785 | 1,860 | 1,713 | 1,735 |
| Expenses + | 689 | 745 | 813 | 1,054 | 1,291 | 1,234 | 1,398 | 1,602 | 1,765 | 1,518 | 1,531 | 1,492 | 1,503 |
| Operating Profit | 182 | 181 | 201 | 242 | 298 | 273 | 323 | 341 | 258 | 267 | 328 | 220 | 232 |
| OPM % | 21.0% | 20.0% | 20.0% | 19.0% | 19.0% | 18.0% | 19.0% | 18.0% | 13.0% | 15.0% | 18.0% | 13.0% | 13.0% |
| Other Income + | 2 | 2 | -3 | 4 | 2 | -12 | 5 | 5 | 5 | 2 | 5 | -73 | -63 |
| Interest | 60 | 62 | 48 | 49 | 58 | 52 | 36 | 31 | 48 | 56 | 75 | 62 | 60 |
| Depreciation | 64 | 67 | 69 | 86 | 93 | 82 | 85 | 96 | 109 | 118 | 134 | 164 | 167 |
| Profit before tax | 60 | 53 | 80 | 112 | 149 | 127 | 206 | 219 | 105 | 96 | 124 | -78 | -58 |
| Tax % | 32.0% | 23.0% | 16.0% | 31.0% | 31.0% | 33.0% | 36.0% | 27.0% | 26.0% | 27.0% | 27.0% | -38.0% | — |
| Net Profit + | 40 | 41 | 68 | 77 | 103 | 84 | 133 | 160 | 78 | 70 | 91 | -49 | -34 |
| EPS in Rs | 3 | 3 | 5 | 6 | 8 | 7 | 11 | 13 | 6 | 6 | 7 | -4 | -3 |
| Dividend Payout % | 20.0% | 20.0% | 15.0% | 13.0% | 14.0% | 18.0% | 19.0% | 12.0% | 19.0% | 21.0% | 19.0% | -15.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 516 | 547 | 589 | 653 | 732 | 792 | 909 | 1,043 | 1,109 | 1,163 | 1,238 | 1,174 |
| Borrowings + | 547 | 505 | 598 | 635 | 661 | 646 | 610 | 675 | 748 | 818 | 765 | 684 |
| Other Liabilities + | 212 | 206 | 177 | 237 | 268 | 306 | 370 | 470 | 504 | 482 | 502 | 483 |
| Total Liabilities | 1,292 | 1,275 | 1,379 | 1,542 | 1,686 | 1,768 | 1,913 | 2,213 | 2,385 | 2,487 | 2,529 | 2,365 |
| Fixed Assets + | 639 | 623 | 668 | 634 | 713 | 735 | 713 | 879 | 948 | 1,071 | 1,364 | 1,333 |
| CWIP | 62 | 66 | 63 | 118 | 79 | 161 | 254 | 295 | 412 | 414 | 121 | 94 |
| Investments | 3 | 3 | 4 | 3 | 1 | 1 | 1 | 11 | 5 | 5 | 10 | 10 |
| Other Assets + | 588 | 583 | 645 | 788 | 893 | 871 | 946 | 1,028 | 1,020 | 997 | 1,034 | 928 |
| Total Assets | 1,292 | 1,275 | 1,379 | 1,542 | 1,686 | 1,768 | 1,913 | 2,213 | 2,385 | 2,487 | 2,529 | 2,365 |
| Equity Capital | 16 | 16 | 16 | 16 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 102 | 186 | 163 | 139 | 186 | 285 | 229 | 294 | 315 | 187 | 280 | 302 |
| Cash from Investing Activity + | -43 | -64 | -102 | -110 | -125 | -164 | -156 | -284 | -292 | -174 | -136 | -145 |
| Cash from Financing Activity + | -69 | -124 | -63 | -25 | -55 | -101 | -97 | -6 | -8 | -27 | -144 | -160 |
| Net Cash Flow | -10 | -2 | -2 | 4 | 6 | 20 | -24 | 4 | 15 | -14 | 0 | -3 |
| CFO/OP | 63 | 110 | 91 | 68 | 73 | 113 | 85 | 107 | 134 | 81 | 94 | 144 |
| Free Cash Flow | 54 | 127 | 58 | 33 | 57 | 127 | 71 | 21 | 13 | -17 | 144 | 154 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 23.22% | 21.85% | 21.06% | 21.32% | 20.79% | 21.61% | 21.65% | 21.76% | 21.75% | 21.78% | 22.51% | 22.92% |
| Promoters | 68.85% | 68.85% | 68.85% | 68.85% | 68.85% | 68.85% | 68.85% | 68.85% | 68.85% | 68.85% | 68.85% | 68.85% |
| FII | 4.81% | 6.14% | 6.55% | 6.66% | 6.78% | 6.06% | 5.7% | 5.35% | 4.23% | 2.31% | 1.44% | 0.98% |
| DII | 3.11% | 3.15% | 3.53% | 3.17% | 3.58% | 3.48% | 3.8% | 4.03% | 5.15% | 7.05% | 7.2% | 7.23% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Hikal Limited (this stock) | 2,687 | 63.4 | 2.24 | 2.21% |
| Vimta Labs Limited | 2,679 | 44.1 | 7.76 | 13.5% |
| Dishman Carbo Amcis Ltd | 2,546 | 140.0 | 0.38 | 1.58% |
| Sakar Healthcare Limited | 2,527 | 70.0 | 7.78 | 9.99% |
| Shukra Pharmaceuticals L | 2,465 | 72.6 | 27.27 | 28.9% |
| Fischer Medical Venture L | 2,401 | 98.1 | 5.85 | 8.91% |
| Indoco Remedies Ltd. | 2,306 | — | 2.45 | -9.36% |
Which Mutual Funds Hold Hikal Limited?
Frequently Asked Questions about Hikal Limited
Hikal Limited (HIKAL) closed at ₹208.8 on NSE on 28 September 2026, down 8.78 (4.04%) from the previous close.
Hikal Limited trades on the NSE (National Stock Exchange of India) under the symbol HIKAL.
Hikal Limited has a trailing twelve-month P/E (price-to-earnings) ratio of 63.4.
Hikal Limited has a dividend yield of 0.28%.
Hikal Limited's 52-week high is ₹261.0 and its 52-week low is ₹146.0.
Hikal Limited has a market capitalisation of ₹2,687 crore.
Hikal Limited has a TopFund Quality Score of 43/100 (Weak), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Hikal Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.